Analysts’ Top Healthcare Picks: Crispr Therapeutics AG (CRSP), Faeth Therapeutics (FTH)

Analysts at H.C. Wainwright and J.P. Morgan reiterated Buy ratings on Crispr Therapeutics (CRSP) with price targets of $80 and $73.09, respectively. Faeth Therapeutics (FTH) received a Buy rating and $55 price target from JonesTrading, with a consensus target of $57.60. Both stocks have significant upside potential according to analysts.

Original reporting
Published Nov 4, 2026, 10:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 8:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Analysts’ Top Healthcare Picks: Crispr Therapeutics AG (CRSP), Faeth Therapeutics (FTH) — source image
Decision brief

The 30-second read

$CRSPBullishMed
01

Why it matters

Analyst upgrades can trigger short-term buying pressure, especially for small‑cap biotech stocks where coverage is scarce.

02

Market read

Both stocks receive fresh, higher price targets, offering a short‑term trade idea for bullish investors in the healthcare sector.

03

What to watch

Potential regulatory or clinical trial setbacks could negate the upside.

Relevance 6/10Novelty 6/10Timing: today

Background

The article summarizes fresh analyst coverage for two biotech firms, providing new price targets and reaffirmed Buy ratings.

Company-level read

Ticker impact

$CRSPBullishHigh confidence
Context

Analyst Mitchell Kapoor reiterated a Buy rating and set a new $80 price target for Crispr Therapeutics AG, up from the prior level.

Expected impact

likely upward pressure as investors price in the $80 target.

Evidence & confidence

Buy rating and a 57% upside target constitute fresh, material analyst coverage.

$FTHBullishHigh confidence
Context

Analyst Boris Peaker maintained a Buy rating and raised the price target to $55 for Faeth Therapeutics.

Expected impact

likely upward pressure as the $55 target implies a 177% upside.

Evidence & confidence

New rating and target provide fresh catalyst for the stock.

Market effects

Both upgrades highlight continued bullish sentiment in the healthcare/biotech sector.

U.S. biotech investors may reallocate capital toward CRSP and FTH.

Limited to investors tracking biotech equities; no broader macro effect.

Counterpoint

The price targets may be overly optimistic given the companies' early-stage pipelines.

Key entities

  • Crispr Therapeutics AG

    Gene‑editing biotech with a new $80 price target.

  • Faeth Therapeutics

    Biotech firm receiving a $55 price target.

Related articles

$FTHMed

Why is Faeth Therapeutics stock surging today?

Faeth Therapeutics (FTH) stock rose 10.1% in pre-market trading after presenting Phase II endometrial cancer data at the Jefferies Global Healthcare Conference, showing a 33% overall response rate. The company also announced a clinical partnership with Roche. H.C. Wainwright reiterated its Buy rating and $60 price target, citing a 55% stock decline since November 9 as disconnected from clinical progress.

$FTHMed

Faeth Therapeutics stock gets $60 target on Roche collaboration

Faeth Therapeutics (FTH) received a $60 price target from H.C. Wainwright after announcing a clinical trial collaboration with Roche to evaluate PIKTOR in combination with giredestrant for advanced breast cancer. The stock has fallen 55% since November 9, trading at $9.28. Analysts cite undervaluation and positive Phase 2 trial results for PIKTOR in endometrial cancer, with a 33% response rate.

$CRSPMed

Seawolf Therapeutics San Diego $100M Sanofi DNA Deal

Seawolf Therapeutics, a San Diego biotech, raised $100M and partnered with Sanofi for a deal potentially worth $1.2B. The company's TRIDENT platform aims to enable repeat dosing of gene therapies. Seawolf's lead program targets metabolic diseases, with human trials expected by 2028. Investors include Eli Lilly, Novartis Venture Fund, and CRISPR Therapeutics.

$FTHMedAI 8/10

Baird reiterates Faeth Therapeutics stock rating on PIK-201 data

Baird reiterated an Outperform rating on Faeth Therapeutics (FTH) with a $57 price target, citing positive PIK-201 data. The stock is down 35% in a week, trading at $12.79. Analysts highlight its potential in endometrial and breast cancer, with a market cap of $333M and strong financial metrics. Recent clinical trials showed a 33% response rate in endometrial cancer.